E-cigarette maker Juul to explore options including financing

Business
Jul.18.2022

(Reuters) -Juul Labs Inc said on Friday it is in the early stages of exploring several options including financing alternatives, as the company deals with lawsuits and a probable ban on sales of its e-cigarettes by U.S. health regulators.

 

E-cigarette maker Juul to explore options including financing

Bloomberg News earlier reported, citing sources, that Juul's bankers at Centerview Partners are sounding out investors for a possible $400 million first-lien term loan due August 2023. (https://bloom.bg/3O9qStl)

The proceeds would help refinance an existing term loan, which has around $394 million outstanding and matures on the same date, the report added.

A spokesperson for Juul told Reuters that the company is looking at options to protect its business and to address the "impact of the FDA's now stayed order so we can continue offering our products to adult consumers who have or are looking to transition away from traditional cigarettes."

 

Centerview Partners declined to comment when contacted by Reuters.

 

Bloomberg News in its report said Juul was also considering a new $150 million second-lien term loan, which may have an August 2024 maturity, to help pay down some of the first-lien term loan and to increase liquidity, the report said.

 

Financing proposals for either loan are due July 21, according to the report.

 

Last month, the Food and Drug Administration (FDA) blocked sales of Juul e-cigarettes and said the applications "lacked sufficient evidence" to show that sale of the products would be appropriate for public health.

 

However, Juul appealed the agency's order and earlier this month FDA put on hold its ban saying it would do an additional review of the company's marketing application.

 

(Reporting by Ananya Mariam Rajesh in Bengaluru; Editing by Shailesh Kuber)

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Hungary Moves to End BAT-Backed Tobacco Supply Monopoly Eight Years Early After $200 Million in Profits, With No Compensation Planned
Hungary Moves to End BAT-Backed Tobacco Supply Monopoly Eight Years Early After $200 Million in Profits, With No Compensation Planned
Hungary's government announced on November 18, 2026, plans to terminate the exclusive tobacco retail supply concession held by Országos Dohányboltellátó (ODBE) on June 1, 2027, approximately eight years before the contract's scheduled expiry in 2035. ODBE is owned 49% by a Hungarian subsidiary of British American Tobacco (BAT) and 51% by Tabán Trafik. It has served as the exclusive supplier to Hungary's licensed tobacco retail network since 2015. The proposed legislation would end the concession without compensation and allow other qualified suppliers and tobacco wholesalers to serve retailers directly. ODBE generated HUF 67.3 billion (approximately $200 million) in after-tax profit between 2015 and 2025 and distributed nearly HUF 64 billion ($191 million) in dividends. The bill also proposes changes to retail margins, inventory rules, payment arrangements and procurement penalties, including those affecting heated tobacco products.
company
Nov.19 by 2Firsts Perspectives
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
Special Report | Altria's NACS Booth Raises Questions Over U.S. Tobacco Advertising Warnings
During its coverage of Altria's booth at NACS Show 2026, 2Firsts documented product displays that prompted questions about U.S. tobacco advertising warning requirements. Following public comments from a former FDA official, 2Firsts sought responses from Altria and independently consulted U.S. regulatory lawyer Azim Chowdhury. Altria maintained that its B2B communications complied with applicable laws, while Chowdhury explained that federal warning rules provide no general trade-show exemption for e-cigarettes and nicotine pouches. The special report examines the broader regulatory implications.
Nov.04
Australia's Illicit Tobacco Market May Have Turned After Five Years of Growth, With Estimates Showing Up to 25% Decline Amid Tax-Cut Debate
Australia's Illicit Tobacco Market May Have Turned After Five Years of Growth, With Estimates Showing Up to 25% Decline Amid Tax-Cut Debate
New Australian government estimates released on November 15, 2026, suggest that the country's illicit tobacco market may have contracted for the first time following five years of growth. Estimated market volume fell from a previous peak of 5,972 tonnes to a range of 4,453–5,893 tonnes. The government attributed the change to stronger border enforcement and coordinated domestic operations. Australian Border Force seized more than 2,300 tonnes of illicit tobacco and 13.2 million illicit vaping products in 2025–26, followed by approximately 730 tonnes of illicit tobacco in the first quarter of 2026–27. Separate experimental estimates from the Australian Bureau of Statistics indicate that illicit sources accounted for approximately 80% of nicotine consumption in 2025.
Regulations
Nov.16
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10